Background: High blood pressure is an important public health concern because it is highly prevalent and a risk factor for adverse health outcomes, including coronary heart disease, stroke, decompensated heart failure, chronic kidney disease, and decline in cognitive function. Observational studies show a progressive increase in risk associated with blood pressure above 115/75 mm Hg. Prior research has shown that reducing elevated systolic blood pressure lowers the risk of subsequent clinical complications from cardiovascular disease. However, the optimal systolic blood pressure to reduce blood pressure-related adverse outcomes is unclear, and the benefit of treating to a level of systolic blood pressure well below 140 mm Hg has not been proven in a large, definitive clinical trial. Purpose: To describe the design considerations of the Systolic Blood Pressure Intervention Trial (SPRINT) and the baseline characteristics of trial participants. Methods: The Systolic Blood Pressure Intervention Trial is a multicenter, randomized, controlled trial that compares two strategies for treating systolic blood pressure: one targets the standard target of \140 mm Hg, and the other targets a more intensive target of \120 mm Hg. Enrollment focused on volunteers of age 50 years (no upper limit) with an average baseline systolic blood pressure 130 mm Hg and evidence of cardiovascular disease, chronic kidney disease,
Introduction, background, and rationale
Hypertension is highly prevalent in the adult population of the United States, especially among those aged .60 years and is estimated to affect approximately 1 billion adults worldwide. 1 By age 50 years, isolated systolic hypertension is the most common form of hypertension, 2 and the importance of blood pressure, especially systolic blood pressure, as an independent risk factor for coronary events, stroke, heart failure, and progressive chronic kidney disease including endstage renal disease is well documented. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] There is also substantial epidemiologic and some clinical trial evidence supporting a role for hypertension therapy in reducing risk for adverse changes in brain structure and function, including dementia, cognitive decline, and cerebrovascular disease. [14] [15] [16] [17] [18] [19] [20] The Global Burden of Disease Study identified elevated blood pressure as the leading risk factor, among 67 factors studied, for worldwide mortality and disability-adjusted life years during 2010. 21 Clinical trial experience has demonstrated that treatment of hypertension reduces cardiovascular disease outcomes, including incident stroke (35% to 40%), myocardial infarction (15% to 25%), and heart failure (up to 50%). 3, 22, 23 The optimal target for systolic blood pressure (SBP) lowering is uncertain. Clinical trials with SBP targets \150 mm Hg (Systolic Hypertension in the Elderly Program (SHEP) and Hypertension in the Very Elderly Trial (HYVET)) have demonstrated reduction in cardiovascular disease outcomes, including incident stroke. 24, 25 Observational studies document a progressive increase in risk of cardiovascular disease events as blood pressure rises above 115/75 mm Hg. 10 However, lowering to \120 mm Hg may be harmful or fail to produce benefits and could be unnecessarily costly and burdensome. [26] [27] [28] [29] [30] [31] [32] [33] Clarification of the most desirable SBP goal during hypertension treatment is important for the health of the general population.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure trial, which was restricted to participants with diabetes mellitus who had normal or near-normal kidney function, tested the hypothesis that more intensive reduction in SBP to \120 mm Hg is beneficial compared to the frequently recommended target SBP of \140 mm Hg. ACCORD did not demonstrate a benefit for treatment to the lower target for a composite cardiovascular disease outcome (hazard ratio 0.88, 95% confidence interval (CI): 0.73-1.06, p = 0.20). However, the confidence limit did not exclude a benefit as large as a 27% improvement in the composite cardiovascular disease outcome. 32 A definitive clinical trial in non-diabetic hypertensive participants to determine whether lowering SBP \120 mm Hg reduces clinical events more than lowering SBP to \140 mm Hg was designated by a National Heart, Lung, and Blood Institute (NHLBI) Expert Panel in 2007 34 as the most important hypothesis to test regarding the prevention of hypertension-related complications. This article describes the design of the Systolic Blood Pressure Intervention Trial (SPRINT), which aims to address this question. This article is a summary of our protocol which is publically available. 35 
Study organization
The SPRINT organizational structures and responsibilities are similar to many previous multicenter clinical trials. Four institutes of the National Institutes of Health (NIH) co-sponsor SPRINT. The NHLBI initiated the study, and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a co-sponsor of the main SPRINT trial. The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA) are jointly sponsoring the cognitive sub-study, known as Systolic Blood Pressure Intervention Trial: Memory and cognition IN 
Study design decisions

Overall design
The objective of SPRINT is to test whether reducing SBP to \120 mm Hg will reduce cardiovascular disease events defined as the composite of non-fatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, non-fatal stroke, non-fatal acute decompensated heart failure, and death from cardiovascular disease. Research teams submitted proposals to NIH in May 2008 in response to a request for proposals issued by NIH in February 2008. After the contracts were awarded in September 2009, the SPRINT Steering Committee refined the overall study design. This process led to a review by an NIH-appointed Protocol Review Committee in June 2010 and final approval by NIH. Below we discuss the design considerations for SPRINT.
Eligibility, recruitment, retention, and adherence
The SPRINT inclusion criteria are presented in Table 1 ; exclusion criteria are detailed in the protocol; 35 two major exclusion criteria include diabetes mellitus and stroke. A major goal was to recruit a sample that would provide maximum generalizability and safety, adequate event rates to achieve the planned level of statistical power, and feasibility to meet the trial's enrollment objectives. Other goals included assessing whether persons with and without chronic kidney disease and older and younger participants in diverse population subgroups differ in their response to hypertension treatment and whether the treatment might slow down age-related decline in cognition and reduce dementia rates. Hence, SPRINT was to include a diverse population with hypertension and existing cardiovascular disease, existing chronic kidney disease, or an elevated estimated risk for cardiovascular disease based on age and other risk factors. 36 The overall target was to randomize 9250 participants.
Within the 9250 target, targets were set for three subgroups: 4300 (46%) with chronic kidney disease (estimated glomerular filtration rate 20-59 mL/min/ 1.73 m 2 ), 3700 (40%) with clinical or subclinical cardiovascular disease, and 3250 (35%) seniors (75 years old). Additional targets included enrolling 50% women and 40% minorities. The recruitment targets were closely monitored. Participant recruitment began on 8 November 2010 but proceeded more slowly than planned, and achieving the original chronic kidney disease, cardiovascular disease, and senior targets was more challenging than expected ( Figure 1 ). From 4 November 2012 through 15 March 2013, recruitment was focused on enrolling seniors or participants with existing chronic kidney disease or cardiovascular disease. The overall enrollment experience is shown in the consolidated standards of reporting trials (CONSORT) diagram ( Figure 2 ).
The SPRINT study also recruited participants into two important nested sub-studies, SPRINT MIND and Systolic Blood Pressure Intervention Trial: Memory and cognition IN Decreased hypertension magnetic resonance imaging (SPRINT MIND MRI), both of which were pre-specified in the NIH request for proposals (RFP). While all SPRINT participants are assessed for incident dementia (see below), our target was a subset of 2800 SPRINT participants to undergo more extensive cognitive assessment than that performed in the total sample, with the goal of evaluating the impact of the intervention on decline in cognitive function. A smaller number of 640 SPRINT MIND participants attending clinics located near a SPRINT MIND MRI center was targeted to be recruited into the SPRINT MIND MRI sub-study.
Attention to adherence and retention began before enrollment, during the screening process, and continues throughout the trial. During screening, individuals who demonstrated a significant risk for non-adherence to study medication or for completing study visits were excluded from trial participation. Once participants Table 1 . SPRINT inclusion criteria. To be eligible, a participant must meet 1, 2, and 3. were enrolled, a baseline assessment of adherence using standardized, valid adherence measures in conjunction with assessment of behavioral ''red flags'' by clinic staff allowed for early identification of potential problems so that study resources could be devoted to improving adherence and retention for these individuals. Throughout the trial, ongoing monitoring of adherence is critical for identifying low adherence and enabling clinic staff to intervene and address problems as they develop.
Study procedures, including obtaining written informed consent from all participants, were approved in advance by relevant Institutional Review Boards.
Intervention
Participants were randomized to one of two SBP targets: \120 and \140 mm Hg. The intervention is a treatment algorithm similar to that used in the ACCORD trial, which produced average systolic blood pressures of 119 mm Hg and 134 mm Hg in the Intensive and Standard Treatment groups, respectively (Figures 3 and 4 ). 32 Representative medications from all major classes of antihypertensive agents are provided by the trial at no cost to the participants. Other antihypertensive medications can be used by SPRINT investigators but are not provided by the trial. The protocol recommended that antihypertensive regimens should include one or more drug classes with the strongest evidence for capacity to prevent cardiovascular disease outcomes: thiazide-type diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), with priority for prescription of thiazide-type diuretics. 3, 37 However, clinical center investigators are given discretion regarding which drugs to use at initiation and during intensification of therapy. Loop diuretics are recommended for participants with advanced chronic kidney disease. Use of beta-adrenergic blockers is encouraged in participants with coronary artery disease. Chlorthalidone is encouraged as the primary thiazide-type diuretic and amlodipine as the preferred CCB, since they have the most robust evidence for the prevention of cardiovascular disease outcomes and blood pressure reduction within their respective classes. 38, 39 Antihypertensive drug classes with guideline recommendations for specific non-hypertensive indications can be used in place of other agents in order to achieve and maintain SBP targets (e.g. use of ACE inhibitors and ARBs in participants with chronic kidney disease). The SPRINT formulary is presented in Table 2 .
In both groups, participants are evaluated monthly for the first 2 months, and thereafter every 3 months. Monthly visits continue in the intensive group until a SBP \120 mm Hg is achieved or no more titration is planned and in the standard group whenever a SBP 160 mm Hg is noted. Additional visits can be scheduled as needed for monitoring medications and safety.
For most participants in the intensive group, a twoor three-drug regimen was initiated at randomization (occasionally only one drug for participants 75 years). Drug doses are increased and/or additional antihypertensive medications are added at monthly visits until the target of \120 mm Hg is reached or the investigator decides no further antihypertensive medications should be added. ''Milepost Visits'' are scheduled every Figure 2 . CONSORT diagram. Inclusion/exclusion criteria were applied in the order asked and are described in greater detail in Table 1 . BP/meds refers to the allowable SBP depending on the number of antihypertensive medications taken. High-risk factors included 75 years of age, history of clinical or subclinical cardiovascular disease other than stroke, chronic kidney disease, or having a 15% 10-year Framingham risk score for cardiovascular disease. Participants without at least one were excluded. Miscellaneous reasons for exclusion include a known secondary cause of hypertension that causes safety concern (N = 17), significant proteinuria within the past 6 months (N = 67), history of diabetes (N = 116) or stroke (N = 49), end-stage renal disease or polycystic kidney disease (N = 7), glomerulonephritis treated with immunosuppressive therapy (N = 1), symptomatic heart failure within last 6 months or left ventricular ejection fraction \35% (N = 15), expected survival less than 3 years (N = 5), cancer diagnosed within the last 2 years (N = 33), living in the same household as another SPRINT participant (N = 11), organ transplant (N = 2), indication for a specific blood pressure medication that is not currently being taken without documented intolerance (N = 16), cardiovascular event, procedure, or hospitalization for unstable angina within the last 3 months (N = 6), factors likely to limit adherence (N = 319), participation in another trial (N = 30), unintentional weight loss .10% in last 6 months (N = 8), and pregnancy, trying to become pregnant, or of child-bearing potential and not practicing birth control (N = 1).
CONSORT: consolidated standards of reporting trials; BP: blood pressure; meds: medications.
6 months. If the SBP is not \120 mm Hg at a Milepost Visit, an antihypertensive drug from an additional class is added, absent contraindications. For standard group participants, the protocol is designed to achieve a SBP of 135-139 mm Hg, starting with the randomization visit. Dose titration or addition of another drug occurs if SBP is 160 mm Hg at a single visit or 140 mm Hg at two successive visits. Medication may be reduced if the SBP is \130 mm Hg at a single visit or \135 mm Hg at two consecutive visits.
Titration of medications to target is based on a mean of three office blood pressure measurements obtained in the seated position using an automated measurement device (Omron Healthcare, Lake Forest, IL). Blood pressure is also measured 1 min after standing at screening, baseline, 1 month, 6 months, 12 months, and annually thereafter. While standing, participants are asked about symptoms of hypotension (see section ''Safety monitoring'').
All participants are advised to follow lifestyle recommendations and background therapy consistent with current practice guidelines to minimize differences in the effects of non-study strategies that could influence SBP or cardiovascular disease outcomes in the two treatment arms. Specific lifestyle recommendations include weight loss for overweight participants, a hearthealthy diet (e.g. the dietary approaches to stop hypertension (DASH)) with appropriate modifications for participants with chronic kidney disease, reducing sodium intake and alcohol consumption below maximum recommended levels, regular aerobic exercise, and smoking cessation. 3
Hypotheses and choice of outcomes
The primary hypothesis for SPRINT is that treating to a SBP target of \120 mm Hg (the intensive intervention) compared to a SBP target of \140 mm Hg (the standard intervention) will reduce the composite outcome of non-fatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, non-fatal stroke, non-fatal acute decompensated heart failure, and death from cardiovascular disease. Three subgroups are of particular interest since the intervention effect may be modified by the baseline values defining them: participants with (estimated glomerular filtration rate \60 mL/min/1.73 m 2 ) and without chronic kidney disease, race (Black or non-Black), and participants \ or 75 years. We selected a composite primary outcome for three reasons. First, there is previous evidence that each component of the primary outcome may be modifiable with intensive blood pressure reduction. 12, 24, 25, 40, 41 Second, use of a primary outcome based on a single clinical event would have resulted in a sample size that is unfeasible. Third, the integrated effect of the intervention on overall cardiovascular disease outcomes (or mortality) is the most important clinical question upon which a significantly lower blood pressure goal would be widely recommended. SPRINT prespecifies three types of secondary outcomes: (1) secondary outcomes to support the primary analysis, including components of the primary composite outcome, total mortality, and a composite of the primary composite with total mortality (i.e. cardiovascular disease-free survival); (2) kidney outcomes; and (3) brain outcomes. Additional secondary cardiovascular disease outcomes include peripheral arterial disease, coronary revascularization, transient ischemic attack, left ventricular hypertrophy (LVH) on ECG, and atrial fibrillation or flutter. Peripheral arterial disease includes carotid and peripheral revascularization, abdominal aortic aneurysm (AAA) repair, and other objectively defined peripheral arterial disease events.
The main secondary kidney outcome, restricted to the chronic kidney disease subgroup, is a composite of a 50% decrease in estimated glomerular filtration rate from baseline or incident end-stage renal disease. Among the non-chronic kidney disease subgroup, the kidney outcomes are (1) a decrease in estimated glomerular filtration rate by .30% to \60 mL/min/1.73 m 2 and (2) incident albuminuria, defined as a doubling of urinary albumin-to-creatinine ratio from a value of \10 mg/g to a value of .10 mg/g. The second of these also applies to the chronic kidney disease subgroup. These kidney outcomes are ascertained by laboratory tests obtained during regularly scheduled study visits, except for end-stage renal disease, which is ascertained by history and review of clinical records.
The main secondary brain hypothesis is that incidence of all-cause dementia will be lower in the intensive compared to the standard group. We also hypothesize that compared to the standard group, the intensive group will have slower decline in a composite measure of general cognitive function across all domains of cognition (measured in the SPRINT MIND participants) and a lower load of small-vessel ischemic disease and higher total brain volume (measured in the SPRINT MIND MRI participants).
Consistency of effects of the intervention on the cardiovascular primary outcome will be examined in subgroups defined by six baseline variables (chronic kidney disease vs non-chronic kidney disease, Black vs non-Black, age ( vs \75 years), gender, presence vs absence of cardiovascular disease (see Table 1 ), and tertiles of baseline systolic blood pressure). Subgroup analyses will also be performed for the kidney outcomes. These subgroups are defined by race, age, gender, baseline urinary albumin-to-creatinine ratio (.300 mg/g vs 300 mg/g) and baseline estimated glomerular filtration rate (\vs the median). For dementia and the cognitive outcomes, we will examine the subgroups for the primary outcome, mild cognitive impairment at baseline (presence vs absence), and baseline orthostatic hypotension (presence vs absence, defined as an orthostatic SBP decrease of 20 mm Hg or a diastolic blood pressure decrease of 10 mm Hg).
Health-related quality of life is assessed in the total SPRINT sample using the Veterans Rand Short-Form 12 (VR-12), 42, 43 the EuroQol-5D-3L, 44 and the Patient Health Questionnaire-9 (PHQ-9). 45, 46 In addition, two items developed by the SPRINT Health-related Quality of Life Subcommittee are used to assess participant satisfaction with antihypertensive medications and treatment for hypertension. In a health-related quality of life subsample, the Falls Self-Efficacy Scale International 47 is assessed. Among women, the Female Sexual Function Index (FSFI) 48, 49 is assessed, and among men, the International Index of Erectile Function 5-item version (IIEF-5) 50 is assessed.
Measurement, ascertainment, and follow-up
The algorithm for classifying myocardial infarction is presented in Table 3 . The definition includes myocardial infarction that occurred during surgery or a procedure and myocardial infarction aborted by thrombolytic therapy or procedure. Silent myocardial infarction, determined using 12-lead ECG at years 2 and 4 and the close-out visit compared to baseline, is determined centrally in the absence of clinically detected myocardial infarction using the Minnesota ECG classification. 52 The diagnosis of non-myocardial infarction acute coronary syndrome requires hospitalization for evaluation, with documented new or changing cardiac ischemic symptoms. Furthermore, confirmatory evidence of coronary artery disease is required. Stroke is defined as the rapid onset of focal neurologic symptoms, headache, or meningismus not due to other conditions (e.g. central nervous system infection), plus a lesion on brain imaging consistent with symptoms except when death occurs within 24 h without resolution of symptoms. 53, 54 Clinical strokes are subtyped using the Causative Classification of Stroke (CCS) system. 55, 56 Diagnosis of heart failure requires a hospitalization or emergency department visit requiring treatment with infusion therapy for a clinical syndrome that presents with multiple signs and symptoms consistent with cardiac decompensation or inadequate cardiac pump function. 57 This outcome includes heart failure with preserved or reduced left ventricular ejection fraction. Cardiovascular disease death includes fatal coronary heart disease, 51 sudden cardiac death, heart failure, stroke, and other noncardiac cardiovascular events adjudicated centrally as the underlying cause of death. Fatal cardiovascular disease events are defined based on temporal relationship to a documented event (e.g. hospitalization for myocardial infarction) or postmortem findings of an acute cardiovascular disease event.
Cardiovascular disease outcomes are ascertained primarily through surveillance for self-reported events, review of pertinent medical records, and ECG collection. Clinical events are ascertained in both arms only every 3 months during follow-up using a structured interview to minimize ascertainment bias. Deaths are investigated at any time the clinical site staff becomes aware of a potential death.
Blood samples are collected at randomization and at months 1, 3, 6, 12, and then every 6 months until the close-out visit. Urine samples are collected at randomization and at months 1, 6, 12, and then yearly through month 60. DNA is extracted from wholeblood samples collected at randomization. The analytes measured and methods used to measure them are shown in Table 4 .
SPRINT MIND
The primary outcome of the MIND component of SPRINT is all-cause dementia. This outcome is assessed using a screening battery and an extended cognitive assessment battery. Dementia incidence is assessed in SPRINT using a three-step process. All SPRINT participants undergo a cognitive function screening battery at baseline, 2 and 4 years of followup. In participants who score below screening thresholds, the Functional Assessment Questionnaire (FAQ) 58 is administered to a participant contact to identify functional impairment associated with low cognitive scores. An extended cognitive battery is then administered to all participants scoring .0 on the FAQ or a score of 0-1 on the delayed recall component of the Montreal Cognitive Assessment (MoCA). 59 All participants who receive the extended cognitive battery are presented to an expert panel (composed of neurologists, neuropsychologists, and geriatricians with clinical expertise in the diagnosis of dementia) for adjudication of cognitive status. For participants who cannot be assessed in person at follow-up, we attempt to administer a telephone battery. 60, 61 In instances where participants are unable to communicate by telephone, a prespecified proxy contact is administered the Dementia Questionnaire. 62 Structural brain imaging in a subset of at least 640 participants is performed using MRI.
Quality control
Steps to standardize measures include the use of the Central Lab and ECG Reading Center; use of standard 
Statistical analysis, sample size, and power considerations
The primary analysis will use Cox proportional hazards regression to compare time to first occurrence of the primary cardiovascular disease composite endpoint between the randomized groups using all participants under the intention-to-treat principle and two-sided tests at the 5% level. The model will include an indicator for intervention arm as its sole predictor variable with clinical site at randomization as a stratifying factor. Follow-up time will be censored on the date of the last event ascertainment or at death. For the subgroup comparisons described above, we will add terms to the Cox model for the subgroup and the subgroup by treatment interactions and use a likelihood ratio test for the interaction at the 5% level with Hommel adjusted p-values. Other time-to-event data (e.g. incident chronic kidney disease) will be analyzed similarly. Mixed models will be used for continuous outcomes. Interim analyses will be performed on a periodic basis using O'Brien-Fleming boundaries. 63 Several sensitivity analyses are planned. These include inclusion of baseline variables that may modify treatment (e.g. the factors defining the pre-specified subgroups (possibly as continuous predictors), diastolic blood pressure, metabolic syndrome), exploration of missing data on our conclusions, and exploration of competing risks. The missing data analysis will include multiple imputation, an exploration of which variables predict missingness and their inclusion in analytic models, and exploration of several ''worst-case'' scenarios. Additional details are available in our protocol. 35 We assumed a 2-year recruitment period, a maximum follow-up of 6 years, and a loss to follow-up of 2%/yr. With the targeted 9250 participants, we calculated 88.7% power to detect a 20% effect for our primary outcome, assuming a 2.2%/yr event rate in the standard group. We calculated 81.9% power for a 20% effect for the primary outcome in people with chronic kidney disease at baseline assuming a 4%/yr event rate, 84.5% power to detect a 25% effect for the primary outcome among those 75 years old at baseline assuming a 3.5%/year event rate. We have 96.3% power to detect a 20% effect rate for incident dementia assuming an event rate of 3.1%/year.
Safety monitoring
All sites monitor and report serious adverse events to the Coordinating Center. A serious adverse event is an event that is fatal or life threatening, resulting in significant or persistent disability, requiring or prolonging a hospitalization, or is an important medical event that the investigator judges to be a significant hazard or harm to the participant and may have required medical or surgical intervention to prevent one of the other events listed above. 64, 65 Because SPRINT is using US Food and Drug Administration (FDA)-approved antihypertensive medications with well-documented side effect profiles, adverse events that do not meet the severity threshold of an serious adverse event are not generally collected. However, a specific list of expected events that could be related to the study intervention is being monitored to assess safety. These include emergency department visits for injurious falls, syncope, bradycardia, hypotension, and electrolyte disturbances. Sites are notified of alert values for electrolytes (sodium 132 or .150 mEq/L; potassium \3.0 or .5.5 mEq/ L) and serum creatinine (increase by at least 50% from the last study value to a level 1.5 mg/dL). Sites are also notified of participants with moderate or higher depressive symptoms on the PHQ-9 and participants who are adjudicated as probable dementia. Electrocardiograms are flagged for clinician review if the heart rate is \40 or .120 beats/min or the ECG suggests acute ischemia, ventricular arrhythmias, or new onset atrial fibrillation. Clinically important findings on brain MRI are reported directly to the site physician investigator and study coordinator. Blinded reports of serious adverse events and safety events are monitored by the Safety Committee monthly and unblinded reports are reviewed by the Data Safety and Monitoring Board semiannually.
Web-based trial management
Participant-and visit-specific form sets are created dynamically, and data are entered directly into Webbased forms and saved to the database. The Web-based system allows real-time data entry checks as the data are entered, including verification of eligibility prior to randomization, and range and logic checks on individual data items. The data are immediately available for dynamic reports for study management. The Web site is also used to manage the outcome adjudication process. 66 
Results
Description of the SPRINT sample
Descriptive statistics can be seen in Table 5 . A total of 9361 participants volunteered to participate and met the inclusion criteria, enrolled at 102 clinics within the 5 Clinical Center Networks over a 2.3-year period and will be followed for 4-6 years. Among our sample, 3331 (35.6%) were women, 2636 (28.2%) were at least 75 years old, 2648 (28.3%) had chronic kidney disease, and 1877 (20.1%) had prior cardiovascular disease. Our sample is racially and ethnically diverse with 2802 (29.9%) Black, 984 (10.5%) Hispanic, 5399 (57.7%) White, and 176 (1.9%) participants of other races/ethnicities. The baseline mean systolic and diastolic blood pressures were 139.7 (15.6 (standard deviation (SD))) and 78.1 (11.9) mm Hg. We recruited 2914 for SPRINT MIND and 668 for SPRINT MIND MRI.
Ancillary studies
Ancillary studies utilizing the SPRINT population, biospecimens, and rich database are strongly encouraged, provided these studies do not place undue burden on answering the main study question. As of March 2014, seven ancillary studies have begun. Topics include ambulatory blood pressure, arterial stiffness, cardiac structure and function, atherosclerosis progression in chronic kidney disease, cognitive function and brain structure in chronic kidney disease, kidney tubule damage and dysfunction, as well as genetic influences on nephropathy. Additional ancillary studies are in various stages of development.
Discussion
SPRINT was jointly developed by scientific staff at the NIH and the SPRINT investigators whose efforts are supported by contracts from the NIH awarded via a peer-reviewed competitive process. As SPRINT was developed, key decisions were made in an attempt to balance the trial's scientific goals with the resources available to conduct the study. First, we decided to use the ACCORD Blood Pressure trial as a model for our intervention as it had already been proven to be safe and successful in achieving our SBP targets for the intensive and standard groups. It also facilitates comparison of the effect of this intervention on complementary populations. Our specific target for recruitment of persons 75 years old was established to explore the results of HYVET, 24 which while testing a higher target (SBP \150 mm Hg) than the standard group in SPRINT suggest that benefit of treatment might be larger in persons 80 years than our hypothesized 20% reduction in cardiovascular disease events. HYVET also had an intriguing but non-significant impact on cognition as the study was stopped early. 67 In addition, recent guidelines 68, 69 have questioned the ideal SBP target for older individuals. ACCORD excluded individuals with serum creatinine levels above 1.5 mg/dl and individuals over the age of 80 years. The Secondary Prevention of Small Subcortical Strokes (SPS3) trial, which compared a SBP treatment target of \130 mm Hg to a target of 130-149 mm Hg in participants with a recent lacunar stroke, showed a non-significant reduction in recurrent stroke in the group randomized to the lower target. 70 Our specific goal for participants with chronic kidney disease was to obtain additional information on whether more intensive blood pressure goals would reduce cardiovascular events in these older patients with chronic kidney disease. Two additional trials in the chronic kidney disease population (African American Study of Kidney Disease and Hypertension (AASK) and Modification of Diet in Renal Disease (MDRD)) tested the effects of blood pressure targets that are higher than that being used for the SPRINT intensive treatment group and excluded older participants. 33, 71 In addition, AASK and MDRD specifically targeted kidney outcomes but not cardiovascular disease outcomes. The trial evidence is equivocal about whether hypertension therapy reduces the risk of age-related cognitive decline and dementia, 67 both are recognized as very important public health problems. SPRINT offers an efficient vehicle to address important questions related to cardiovascular, kidney, and dementia prevention. To further enhance the value of SPRINT, we address possible adverse effects of blood pressure lowering using measures of sexual functioning, falls, and fear of falls. In addition, orthostatic blood pressure values and emergency department visits are tracked, as well as hospitalizations and major clinical events. Finally, our events ascertainment process begins with scheduled participant (or surrogate) interviews every 3 months in order to minimize differential ascertainment.
We exceeded our overall recruitment target (9361 actual vs 9250 planned) and our target for minority recruitment (42.3% actual vs 40% planned). However, we did not meet our recruitment targets for enrolling women (35.6% actual vs 50% planned), participants above 75 years old (28.2% actual vs 35% planned), participants with chronic kidney disease (28.3% actual vs 46% planned), and participants with cardiovascular disease (20.1% actual vs 40% planned). Although subgroup enrollment was monitored carefully during the recruitment phase, it proved difficult to enroll the number of participants initially proposed for each of the subgroups while maintaining overall recruitment goal rates. Unless event rates are higher than expected or follow-up is extended, the lower-than-expected enrollment for these subgroups may result in diminished power to explore the primary hypothesis among women, persons above 75 years, and persons with chronic kidney disease.
With the successful completion of enrollment and preliminary safety of the intervention well established, the SPRINT team is focused on participant retention, ensuring adherence to study medications and the assigned SBP targets, ensuring high-quality data collection, monitoring safety, and collecting and adjudicating trial endpoints. Follow-up is scheduled to end in the Fall of 2016. We look forward to sharing the results of this trial with the scientific community in the Fall of 2017 via articles and presentations. We expect that SPRINT will inform the clinical management of hypertension in a diverse population and potentially our ability to prevent outcomes of major public health interest.
